F-1/A: Davion Healthcare Files F-1/A for Nasdaq Direct Listing

Davion Healthcare Plc, a pre-revenue medical device company, filed an amended registration statement for a direct listing on the Nasdaq Global Market, highlighting its non-invasive home test portfolio and a significant licensing deal with NeuRX Health Inc.

Summary

• Davion Healthcare Plc is an Irish public limited company focused on developing and commercializing non-invasive home tests for early detection of health anomalies, including cancers.
• The company has four completed non-invasive home tests: BreastCheck, FootFlow, Testic, and ThermaDerm, all registered as Class I medical devices in the USA (FDA), Europe (CE), and UK (UKCA).
• BreastCheck, the flagship product, is expected to launch in the USA in the first half of 2026 under a global license agreement with NeuRX Health Inc., followed by FootFlow six months later.
• The NeuRX agreement includes a $120 million staged license fee (cash or NeuRX shares) and minimum annual royalties of $10 million for an initial ten-year term.
• Davion is a pre-revenue company, reporting operating losses of €0.3 million for the six months ended June 30, 2025, €1.3 million for 2024, and €5.3 million for 2023.
• The company is pursuing a direct listing of its 25,000,000 ordinary shares on the Nasdaq Global Market under the ticker symbol DAVI, with an expected opening price of $12 per share.
• No new securities are being offered by the company in this registration statement, and Davion will not receive any proceeds from the sale of shares by existing Registered Shareholders.
• Executive officers and directors have waived their 2025 remuneration (€3.6 million annually) until the Nasdaq listing is completed, artificially lowering current operating costs.
• The company has identified material weaknesses in internal controls for the years ended December 31, 2022, 2023, and 2024, leading to a restatement of its 2023 and 2024 financial statements.
• Davion's CEO, Jack Kaye, through his private company Malbrite Ltd, has provided all funding to date and continues to offer financial support to ensure the company can meet its obligations for at least the next 12-18 months.

Sentiment

Score: 6

Explanation: The company presents a mixed outlook. While it has innovative, regulatory-approved products and a significant licensing deal, its pre-revenue status, historical losses, reliance on CEO funding, and identified material weaknesses in internal controls temper the positive sentiment. The direct listing offers market access but also introduces volatility risks. The future success hinges on successful product commercialization and effective management of growth and regulatory compliance.

Positives

• Secured a global manufacturing and distribution agreement with NeuRX Health Inc. for BreastCheck, including a $120 million license fee and minimum annual royalties of $10 million for 10 years.
• Possesses a portfolio of four market-ready, regulatory-approved (Class I medical devices for FDA, CE, UKCA) non-invasive home tests: BreastCheck, FootFlow, Testic, and ThermaDerm.
• The company's products utilize unique thermography technology combined with AI analysis of smartphone images, offering a non-invasive, scalable, and affordable early detection system.
• Management believes there is a large and open global market for its products, particularly BreastCheck, given the high incidence of breast cancer and the desire for home monitoring.
• The CEO, Jack Kaye, has provided continuous financial support through Malbrite Ltd, ensuring liquidity and going concern for at least the next 12-18 months.
• The company has a patent (GB2208671.4) covering the technology behind BreastCheck, with coverage extending to the USA under international patent law.

Negatives

• The company is pre-revenue and has incurred significant operating losses: €0.3 million (H1 2025), €1.3 million (2024), and €5.3 million (2023).
• Current financial results are artificially low due to executive officers and directors waiving €3.6 million in annual remuneration until the Nasdaq listing, indicating a future increase in operating costs.
• The company has a limited operating history with no commercial sales, making it difficult for investors to evaluate its ability to achieve commercial success.
• Significant dependence on a single third-party licensee (NeuRX Health Inc.) for the manufacturing and distribution of BreastCheck, exposing the company to risks beyond its direct control.
• Identified material weaknesses in internal control over financial reporting for 2022, 2023, and 2024, which led to a restatement of prior financial statements.
• The direct listing process lacks the safeguards of an underwritten IPO, potentially leading to higher price volatility and uncertainty in trading volume.
• The company is heavily reliant on the CEO's personal financial support, which is unsecured, non-interest-bearing, and repayable only upon a future capital raise and the company being in a financial position to do so.
• Future issuances of additional ordinary shares (e.g., for listing advisor, incentive plans, acquisitions) will dilute existing shareholders.

Risks

• Ability to sell ordinary shares at or above purchase price due to direct listing's lack of safeguards, potential volatility, and failure of an active, liquid, and orderly market to develop.
• Pre-revenue status and history of operating losses, with dependence on the CEO to fund cash needs.
• Operating model's reliance on a single third-party licensee for manufacturing and distribution of BreastCheck exposes the company to risks beyond its control.
• Future growth depends on demand for BreastCheck and consumer adoption, which may be uncertain.
• Business depends substantially on the continuing efforts of executive officers, and their departure could harm the company.
• 2025 operating results are artificially low and not indicative of future cost structure once publicly listed.
• Dilution of existing shareholders by future issuances of additional ordinary shares.
• Products are subject to various government regulations, including HIPAA and FDA compliance, and potential reclassification could increase costs and delay commercialization.
• Potential inability to fully recover the value of the intellectual property portfolio, leading to significant impairment charges.
• Risks related to status as a foreign private issuer and emerging growth company, which may make shares less attractive to some investors.
• Products are not diagnostic tests and may be misunderstood by consumers or healthcare professionals, leading to misuse or liability claims.
• Limited operating history with no commercial sales, making it difficult to evaluate future success.
• Revenue may be adversely affected if products are not accepted by consumers and healthcare professionals.
• Potential for product liability claims if products do not perform as expected.
• Failure to manage growth effectively could adversely affect business and financial results.
• Failure to properly protect and store consumer medical records may lead to significant liability, litigation, and reputational harm.
• Dependence on third-party mobile platforms (Apple iOS, Google Android) for product functionality, with compliance risks.
• Inability to properly maintain technology infrastructure and comply with evolving laws on artificial intelligence use in healthcare.
• License agreements may be terminated, and securing alternative licensees in a timely manner may not be possible.
• Limited control over sales, pricing, and marketing strategies of licensees, potentially impacting brand and revenues.
• Licensees may market or develop competing products, reducing focus on Davion's portfolio.
• Failure by partners to meet minimum manufacturing or sales targets may result in lower anticipated royalties or milestone payments.
• Disputes with partners could result in costly litigation or arbitration and disrupt commercialization.
• Reliance on third parties creates confidentiality and intellectual property enforcement risks.
• Failure by licensees to maintain adequate product quality and supply may harm reputation and commercial success.
• Need to defend against patent or trademark infringement claims.
• Inability to prevent others from unauthorized use of intellectual property.
• Risks associated with strategic alliances or acquisitions, including loss of proprietary information or integration difficulties.
• Adverse macroeconomic or geopolitical events could affect business.
• No current plans to pay cash dividends, meaning investors may only receive return on investment through share price appreciation.
• Executive management, directors, and their affiliates own a significant percentage of outstanding shares (46%), exerting significant influence over shareholder approval matters.
• If a United States person is treated as owning 10% or more of shares, such holder may be subject to adverse U.S. federal income tax consequences (CFC rules).
• U.S. holders may suffer adverse consequences if the company is treated as a passive foreign investment company (PFIC).
• As an Irish company, investors may face difficulties enforcing their rights due to differences in corporate law and directors/officers residing outside the U.S.

Future Outlook

The company expects to generate its first revenues in the first half of 2026 with the commercial launch of BreastCheck in the USA, followed by FootFlow six months later. It anticipates ongoing investments in product development and market entry preparations. Management plans to recommend a new equity incentive plan post-listing and continues to evaluate market conditions for further product rollouts and potential direct commercialization if licensees underperform. The company believes it has sufficient financial resources for at least the next 12-18 months, supported by the NeuRX agreement and CEO funding, but may seek additional capital in the future.

Management Comments

• "Our strength as a Company at this early stage is twofold, that we possess our own intellectual property, patents and technology; and that to date, there are no other known competitors attempting to utilize like-technologies."
• "Our products, including BreastCheck and FootFlow, use thermography to detect small but meaningful changes in skin surface temperature... By combining this proven film-based technology with artificial intelligence analysis of smartphone images, our products deliver standardized, reliable, and easy-to-understand results."
• "Our commercial strategy is primarily focused on licensing the manufacturing, marketing, sales, and distribution rights for our products to regional or global commercial partners."
• "We are a pre-revenue Company that has incurred operating losses... We will not generate revenues until the commercial launch of our licensed BreastCheck product by our licensee, NeuRX, Health Inc., which is expected in the first half of 2026."
• "Our 2025 financial results are artificially low and not indicative of our future operating costs... As such, our 2025 financial results are artificially low and are not indicative of our future on-going cost structure once the Company is listed."
• "The Company believes as of the date of this Registration Statement, that with its current capitalization, our Chief Executive Officers ongoing financial support, and future contractual inflows, the Company believes that it has sufficient financial resources to meet its obligations for at least the next 12 months."
• "Management believes the Company is a going concern and has sufficient sources of cash to operate the Company for the next twelve months based on the combination of anticipated future cash flows from the NeuRX license agreement and the on-going financial support from Jack Kaye, the Companys CEO."

Industry Context

Davion Healthcare operates in the rapidly evolving Class I medical device industry, specifically focusing on non-invasive home tests for early detection of health anomalies, including cancers. This niche leverages thermography and AI-powered smartphone analysis, positioning the company to capitalize on increasing consumer demand for accessible, at-home health monitoring solutions. The market for early detection and wellness monitoring is growing, driven by factors like increased health awareness and the convenience of home-based testing. The company's licensing model allows it to remain capital-efficient while leveraging established distribution networks, a common strategy for innovators in the medical technology space. However, the industry is subject to stringent regulatory oversight and rapid technological changes, requiring continuous adaptation and robust intellectual property protection.

Comparison to Industry Standards

• Davion's products (BreastCheck, FootFlow, Testic, ThermaDerm) meet Class I regulatory standards for non-invasive medical devices in the USA (FDA), Europe (CE), and the UK (UKCA), which is a self-declaration process for low-risk devices, allowing over-the-counter sales.
• The company's use of thermography combined with AI analysis of smartphone images for early detection is presented as a unique technology with no other known direct competitors utilizing like-technologies, suggesting a potential first-mover advantage in its specific niche.
• BreastCheck is positioned as a non-invasive adjunct to established breast cancer detection procedures like clinical breast examination and mammography, rather than a replacement, aligning with a complementary role in the broader diagnostic landscape.
• The company's commercial strategy of licensing manufacturing, marketing, sales, and distribution rights to regional or global partners (e.g., NeuRX Health Inc.) is a recognized model for capital-efficient innovation in the medical device sector, allowing leverage of existing infrastructure and market reach.
• The company's operating losses are typical for a pre-revenue medical technology company in the development and regulatory approval phase, prior to commercialization.
• The company's reliance on CEO funding and related-party transactions for liquidity is not uncommon for early-stage companies but presents a higher risk profile compared to more established companies with diversified funding sources.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to any legal or administrative proceedings and is not aware of any pending or threatened legal or administrative proceedings against it in any material respects.

Related Party Transactions

• Malbrite Ltd, a private company owned by CEO Jack Kaye, has provided ongoing financial support to Davion Healthcare Plc since its inception, funding operating expenses through non-interest-bearing, unsecured advances repayable only upon a future capital raise.
• In 2023, the company acquired intellectual property rights for €65 million from Davion Healthcare Ltd (a UK company), which was considered a related party transaction as Jack Kaye was a director and shareholder of both the seller and buyer.
• On June 30, 2024, advances from Jack Kaye (through Malbrite Ltd) totaling €4.6 million and €1.0 million in fees due to David Over (Chief Commercial Officer) were converted into 598,246 ordinary shares.
• For the six months ended June 30, 2025, advances from related parties amounted to €0.3 million.
• For the years ended December 31, 2024 and 2023, the company incurred NIL and €1,100,000, respectively, in management fees by Malbrite Limited and Kurdam Inc., companies controlled by Jack Kaye.
• For the years ended December 31, 2024 and 2023, the company incurred €400,000 and €600,000, respectively, in director fees by David Paul Alexander Over, with the balance payable paid in full with share issuances.
• For the year ended December 31, 2023, the company paid approximately €287,000 for marketing services to Tulk House International Limited, a company controlled by David Paul Alexander Over.
• For the years ended December 31, 2024 and 2023, the company incurred NIL and €77,415, respectively, in management fees by Rallinson Limited, a company controlled by Jack Kaye.
• For the years ended December 31, 2024 and 2023, the company incurred NIL and €1,707,178, respectively, in research and development costs by Rallinson Limited.
• For the years ended December 31, 2024 and 2023, the company incurred NIL and €556,279, respectively, in research and development costs by Malbrite Limited.
• In 2025, executive officers Jack Kaye and David Over, along with the four non-executive directors, waived their annual remuneration (€3.6 million combined) until the company's ordinary shares are listed on Nasdaq.

Stakeholder Impact

• **Shareholders**: Existing shareholders will experience dilution from the issuance of 125,000 shares to the listing advisor and potential future equity raises. The direct listing may lead to price volatility due to the absence of traditional IPO safeguards. The 90-day lock-up for directors aims to provide some stability. The concentration of ownership (41.07% by CEO Jack Kaye) means significant influence over company matters.
• **Employees**: Currently, the company has no full-time or part-time employees, with management functions contracted as service providers. Executive officers and directors have waived 2025 remuneration until listing, impacting their immediate compensation but supporting company liquidity.
• **Customers**: Potential customers will benefit from the availability of non-invasive home tests for early health anomaly detection, offering convenience and affordability. However, risks related to product misunderstanding (non-diagnostic nature), data privacy, and reliance on third-party mobile platforms exist.
• **Suppliers**: The company's reliance on third-party licensees for manufacturing and distribution means suppliers' relationships are primarily with the licensees, though disruptions in the supply chain could indirectly affect Davion's royalty revenues.
• **Creditors**: Malbrite Ltd (controlled by CEO Jack Kaye) is a significant creditor, with advances being non-interest-bearing, unsecured, and repayable only upon a future capital raise, indicating a high-risk position for this related-party creditor. Other creditors who converted debt to equity in 2024 have become shareholders.

Next Steps

• Launch BreastCheck in the USA in the first half of 2026 under the global license agreement with NeuRX Health Inc.
• Launch FootFlow in the USA approximately six months after BreastCheck, followed by expansion into Europe and the United Kingdom.
• Review and establish launch dates and regulatory filings for ThermaDerm and Testic.
• Complete the development of the regulatory-compliant database for the proprietary test portal.
• Remediate identified material weaknesses in internal control over financial reporting by hiring additional resources and modifying internal and disclosure controls.
• Establish an Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee upon the effectiveness of the registration statement.
• Recommend a new equity incentive plan for executive officers, independent directors, and third-party service providers once the listing is completed.
• Procure directors and officers liability insurance prior to the commencement of trading on Nasdaq.

Key Dates

Recommendation

Davion Healthcare presents a high-risk, high-reward profile. The company possesses innovative, regulatory-approved products and a substantial licensing agreement with NeuRX Health Inc. that promises significant future revenue. However, it is currently pre-revenue, has a history of operating losses, and is heavily reliant on related-party funding. The direct listing process itself carries inherent volatility risks compared to a traditional IPO. While the long-term potential is notable if commercialization is successful, the immediate future involves significant execution risks, including addressing material weaknesses in internal controls and navigating market acceptance. A 'hold' recommendation is appropriate for investors who are already exposed or considering a speculative position, acknowledging the substantial upside potential balanced against the considerable operational and financial uncertainties in the near term. Further clarity on commercial launch performance and successful remediation of internal control issues would be needed for a more confident 'buy' rating.

Keywords

Davion Healthcare, BreastCheck, Non-invasive home tests, Medical devices, Nasdaq direct listing, Thermography, AI in healthcare, Early cancer detection, NeuRX Health, Class I medical device, SEC filing F-1/A, Corporate governance, Related party transactions, Intellectual property, Ireland company, Healthcare technology